Difference between revisions of "Risk factors for severe disease"
(→What is already known) |
(→Rumours about interaction with medicines) |
||
| Line 6: | Line 6: | ||
=Rumours about interaction with medicines= | =Rumours about interaction with medicines= | ||
==Observations== | ==Observations== | ||
| − | * | + | * The publication by Fang et al. suggests that ACE-inhibitors may increase the risk of Coronavirus infection and severe outcomes. <Ref name="Fang2020"/> |
| − | * | + | * This is so far, the only publication that we know of. |
| − | |||
==Analysis and interpretation== | ==Analysis and interpretation== | ||
| − | * | + | * The study of Fang et al. is relevant and credible. However, the study alone does not (yet) constitute convincing evidence that ACE2-inhibitors are risk factors for COVID19 and severe outcome. The association is plausible, yet requires more study to generate supporting evidence. |
| + | * Notwithstanding the above, it is important to take note of the study of Fang et al. The observation deserves consideration, especially by clinicians treating patients who are in known risk groups for severe COVID19 | ||
| + | |||
==Consequences for action== | ==Consequences for action== | ||
| − | * | + | * Additional studies to find supporting evidence (or refuting) are needed |
| + | * Clinicians should take note of the study of Fang et al., and make decisions on a case by case basis | ||
=References= | =References= | ||
Revision as of 21:13, 16 March 2020
This page collects observations, interpretations, and consequences for action about Risk Factors of SARS-CoV2. Please observe the structure of the page, when you add your content. Please use references where possible. Remember to find the relevant page. For example, if your observation is about Sources, please use that page, instead of posting your content here.
Contents
What is already known
- Recent studies suggest that ACE2 expression is increased in diabetes and treatment with ACE inhibitors and ARBs increases ACE2 expression. Consequently, the increased expression of ACE2 would facilitate infection with COVID-19. This observation makes some researchers hypothesize that diabetes and hypertension treatment with ACE2-stimulating drugs increases the risk of developing severe and fatal COVID-19. [1]
Rumours about interaction with medicines
Observations
- The publication by Fang et al. suggests that ACE-inhibitors may increase the risk of Coronavirus infection and severe outcomes. [1]
- This is so far, the only publication that we know of.
Analysis and interpretation
- The study of Fang et al. is relevant and credible. However, the study alone does not (yet) constitute convincing evidence that ACE2-inhibitors are risk factors for COVID19 and severe outcome. The association is plausible, yet requires more study to generate supporting evidence.
- Notwithstanding the above, it is important to take note of the study of Fang et al. The observation deserves consideration, especially by clinicians treating patients who are in known risk groups for severe COVID19
Consequences for action
- Additional studies to find supporting evidence (or refuting) are needed
- Clinicians should take note of the study of Fang et al., and make decisions on a case by case basis
